EBITDA of the company came in at Rs. 805.7 crore in the quarter while operating margin stood at 25.9%. The better than expected results reported by the pharma major are on the back of strong growth in the US markets.
Nilesh Gupta, Managing Director of the company, was quoted in one of the business dailies saying "Other markets like India are getting back on track also. Our consistent focus on ramping up operational efficiencies has led to higher margins and better profitability,".